Spring direct naar de hoofdnavigatie of de inhoud

Bart van Wezenbeek

Patent attorney

“We use our knowledge and experience to optimize your IP position.”
Home / Experts / Bart van Wezenbeek

Bart van Wezenbeek

  • Life Sciences
  • European Patent Attorney
  • Dutch Patent Attorney
  • Senior Associate

Bart van Wezenbeek started his career in the patent field after he had worked in pharmaceutical research for more than 12 years. He had spent almost three years as a patent information specialist before he switched in 1990 to the patent attorney profession.

More information about Bart

From his biology education and pharmaceutical experience, Bart is well suited to deal with inventions in all biological and life science areas, from food and feed applications to deep sequencing and from microbiological diagnostics to gene therapy. Bart has further specific experience in plant related inventions and molecular biological diagnostics.

Bart is currently heading our patent search and analysis department. Next to his work at V.O. he is involved in the training of trainee patent attorneys and patent information specialists.

Working experience

  • Patent Attorney, V.O. (2002-present) Deputy Justice at the Appeal Court of The Hague (2001-present)
  • Head of the patent department and acting corporate counsel of a small biotech start-up (1995-2002)
  • (Trainee) Patent Attorney in a large pharmaceutical company (1990-1994)
  • Patent Information Specialist in a large pharmaceutical company (1988-1990) Research zoological technician in a large pharmaceutical company (1975-1988)


  • Company counsel, CPO Nijmegen (1997)
  • LLM in Dutch Law, Catholic University Brabant (1994), specializing in intellectual property law
  • Patent information Specialist, Stichting GO, The Hague (1989)
  • MSc in Biology, University of Utrecht (1988), specializing in molecular biology, microbiology and neurobiology


  • The European Patent System. Handbook for the GIIP Offline Campus Learning Module, Global Institute for Intellectual Property, New Delhi, India, 2012.
  • Bart van Wezenbeek. Watch your priorities. In: The Innovation Handbook, Ed. Adam Jolly, 2nd Edition 2010, Kogan Page, London, UK, pages 180-183.
  • G.S.F. Ruigt, J.N. Van Proosdij, L.A.C.M. Van Wezenbeek. A large scale, high resolution, automated system for rat sleep staging. II. Validation and application. Electroencephalography and Clinical Neurophysiology 73: 64-71, 1989.
  • Lambertus A.C.M. Van Wezenbeek, Jeroen A.D.M. Tonnaer, G.S.F. Ruigt. The endegenous muscarinic acetylcholine receptor in Xenopus oocytes is of the M3 subtype, European Journal of Pharmacology 497-500, 1988.

Professional & Community Activities

  • Member of the Disciplinary Board of Appeal of the EPO
  • Member of the Disciplinary Council of the Dutch Association of patent attorneys
  • Member of the legal commission of the Dutch Association of patent attorneys
  • Member of the public relations commission of the Dutch Association of patent attorneys
  • Substitute member of the Professional Qualification Commission of the epi
  • Member of FICPI
  • Member of AIPPI
  • Member of WON
  • Member of PIUG
  • Coordinator and tutor of the CEIPI Basic course in The Hague
  • Tutor on the CEIPI Pre-exam training course in Strasbourg
  • Lecturer on the IPKM program, University of Maastricht
  • Trainer on the WON course for Patent Information Specialists, Stichting GO, Voorburg, The Netherlands


  • English
  • Dutch
  • German

Also see these experts

Hajo Kraak

  • European Patent Attorney
  • Dutch Patent Attorney
  • Partner

Saskia van Doorn

  • European Patent Attorney
  • Dutch Patent Attorney
  • Senior Associate
More experts


Benelux Firm of the Year Award for V.O.

We did it again! During the annual Managing IP’s EMEA  Awards Dinner of 8 March, the Benelux Firm of the Year Award was presented to V.O.Continue reading

Patents are the most important indicator of a company’s powers of innovation

In 2016, the European Patent Office (EPO) granted a record number of patents. The USA submitted the most applications by far (40,076). Germany is placed second (25,086), while the Netherlands and Belgium occupy seventh (6,889) and twelfth (2,186) place respectively. But what does a patent say about a company’s powers of innovation?Continue reading

Finding a breakthrough against antibiotic resistance

It was less than a year ago when, brimming with enthusiasm, he opted for the uncertainty of a start-up. Chemist Andreas A. Bastian started his business AGILeBiotics on the Zernike campus of the University of Groningen. His aim is to achieve a breakthrough in the fight against antibiotic resistance: ‘We have since developed a technology […]Continue reading


Seminar “Innovation box”: the fiscal significance of patents

Engels Conference & Meeting Center, Stationsplein 45, 3013 AK Rotterdam, Netherlands

The "innovationbox" (innovatiebox) is an important fiscal instrument for stimulating innovative business activities. It leads to a lower corporate tax on innovation profits. Since the rules for using the innovation box have changed considerably since 1 January 2017, a prominent role is reserved for patents. More about this event

Job fair

Familie van Rysselberghedreef 2, Ghent, Belgium

On Tuesday 27 March 2018 Ghent University Association organises the 15th edition of Flander's largest job fair. The Afstudeerbeurs takes place in the ICC Ghent, from 12:00 hrs till 18:00 hrs. The Afstudeerbeurs consists of 5 components taking place at the same time and in the same location: the general job market, the Job Market for Young Researchers, the International Jobs Corner, the education and further studies fair and a complementary (free of charge) programme of workshops, information sessions and CV analysis. More about this event

Protecting Your Business

HUBspot Innovate Leiden, Langegracht, Leiden

Building a company costs both time and energy. When you have established something you can be proud of, it's important to protect what is rightfully yours. Intellectual property rights are like any other property right: they allow creators, or owners, of patents, trademarks or copyrighted works to benefit from their own work or investment in a creation. More about this event